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Abstract
Aggressive induction chemotherapy followed by autologous haematopoietic stem cell transplant 
(auto-HCT) is effective for younger patients with mantle cell lymphoma (MCL). However, the 
optimal induction regimen is widely debated. The Southwesterm Oncology Group S1106 trial was 
designed to assess rituximab plushyperCVAD/MTX/ARAC (hyperfractionated cyclophosphamide, 
vincristine, doxorubicin and dexamethasone, alternating with high dose cytarabine and 
methotrexate) (RH) versus rituximab plus bendamustine (RB) in a randomized phase II trial to 
select a pre-transplant induction regimen for future development. Patients had previously untreated 
stage III, IV, or bulky stage II MCL and received either 4 cycles of RH or 6 cycles of RB, followed 
by auto-HCT. Fifty-three of a planned 160 patients were accrued; an unacceptably high 
mobilization failure rate (29%) on the RH arm prompted premature study closure. The estimated 
2-year progression-free survival (PFS) was 81% vs. 82% and overall survival (OS) was 87% vs. 
88% for RB and RH, respectively. RH is not an ideal platform for future multi-centre transplant 
trials in MCL. RB achieved a 2-year PFS of 81% and a 78% MRD negative rate. Premature 
closure of the study limited the sample size and the precision of PFS estimates and MRD rates. 
However, RB can achieve a deep remission and could be a platform for future trials in MCL.
Keywords
mantle cell; bendamustine; Auto-HCT; MRD; hyperCVAD
Introduction
Mantle cell lymphoma (MCL) is an aggressive B cell non-Hodgkin lymphoma that is 
considered incurable with conventional therapy. It represents about 4% of lymphomas in the 
US (The Non Hodgkin’s Lymphoma Classification Project 1997). For younger patients who 
are fit, the therapeutic strategy has been to use aggressive induction chemotherapy followed 
by autologous haematopoietic stem cell transplantation (Auto-HCT). The benefit of 
consolidative Auto-HCT was demonstrated by the European MCL network in a trial that 
compared consolidative Auto-HCT to maintenance interferon and showed improved 
progression-free survival (PFS) in the Auto-HCT arm (median of 39 months versus 17 
months [P = 0.0108])(Dreyling, et al 2005). Although there are a variety of upfront 
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regimens, the optimal induction chemotherapy has not been defined. The goal of induction 
chemotherapy has been to achieve a high rate of complete response (CR) while minimizing 
toxicities.
The R-hyperCVAD (RH) regimen pioneered at MD Anderson Cancer Center contains 
rituximab with hyperfractionated cyclophosphamide, vincristine, doxorubicin and 
dexamethasone, alternating with high dose cytarabine and methotrexate for 6–8 cycles. It 
yields a high CR rate of 87% and overall response rate (ORR) of 97% in single institution 
settings (Romaguera, et al 2005). It has also been tested in the multicentre cooperative group 
setting by the Southwesterm Oncology Group (SWOG) S0213 trial in patients with 
previously untreated MCL, resulting in a CR of 55%, ORR of 86% and 3 year PFS of 66% 
(Bernstein, et al 2013). Single centre studies have demonstrated the feasibility of Auto-HCT 
after abbreviated courses of RH (Till, et al 2008).
Rummel et al (2005) studied the combination of rituximab plus bendamustine (RB) in 
patients with untreated MCL and showed an ORR of 75% and CR of 50%, with minor 
haematological toxicities. This regimen was then compared to RCHOP (rituximab, 
cyclophosphamide, doxorubicin, vincristine, prednisolone) in a large randomized non-
inferiority trial in Europe, which showed similar ORR rates (93% vs. 91%) and CR rates 
(40% vs. 30%) to RCHOP but improved median PFS rates (35 months vs. 22 months), fewer 
haematological toxicities (30% vs. 68%), and fewer infections (37% vs. 50%)(Rummel, et al 
2013). These results were confirmed by the BRIGHT study, which showed that RB is non-
inferior to RCHOP in terms of CR and had less neutropenia (Flinn, et al 2014). However, 
those trials did not include patients consolidated with Auto-HCT.
S1106 was designed to assess RH and RB to select an induction regimen followed by Auto-
HCT consolidation as a platform for development in future trials. The hypothesis was that 
either RH or RB would yield a higher 2-year PFS rate, have fewer toxicities, and allow 
sufficient stem cell mobilization for Auto-HCT consolidation. Besides using radiographic 
imaging to assess for response, we can further characterize response status by the use of 
minimal residual disease (MRD) monitoring. Deep remission as defined by MRD status 
post-induction appears to be a powerful predictor of outcome in both single arm (Liu et al 
2012) and randomized settings (Pott et al 2010). In this study, we use next generation 
sequencing (NGS) to evaluate MRD status as an important biological correlative.
Methods
Patients
Patients in this study (#NCT01412879) were required to have untreated stage III, IV, or 
bulky stage II MCL. Cyclin D1 (CCND1) positivity was confirmed by 
immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH), and all 
pathological material underwent central histological review through SWOG. Other inclusion 
criteria were age ≥ 18 ≤ 65 years, adequate organ function, no prior treatment for MCL, 
bidimensionally measurable disease >1.5 cm by computed tomography (CT), 
fluorodeoxyglucose (FDG)-avid disease by positron emission tomography (PET), and a 
Zubrod performance status score of 0 – 2.
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Study Design and Treatment
This randomized phase II study was conducted by SWOG through the National Clinical 
Trials Network (NCTN) adult groups (SWOG/ECOG-ACRIN/Alliance) mechanism. 
Patients were recruited from January 4, 2012 through June 21, 2013. The study was 
approved by the Institutional Review Board at each study site, and written informed consent 
was obtained from all patients prior to any study-specific procedures, per the Declaration of 
Helsinki. The study was approved and sponsored by the Cancer Therapy Evaluation 
Program (CTEP). Patients were randomized to 4 cycles of RH or 6 cycles of RB (Fig 1). 
Randomization was stratified on the MCL International Prognostic Index (MIPI) score 
(Hoster, et al 2008). The dose of RH and RB were previously described (Bernstein et al 
2013; Rummel et al 2005)(Table I). Only patients achieving CR or PR at restaging were 
eligible to proceed to Auto-HCT consolidation. Patients in the RH arm underwent 
chemotherapy-based stem cell mobilization after cycle 3 with granulocyte colony-
stimulating factor(dose/schedule per institutional standard). Patients in the RB arm 
underwent stem cell mobilization after cycle 6 (within 8 weeks of last dose of RB) using 
rituximab (375 mg/m2) plus cyclophosphamide (1.5 mg/m2). Plerixafor or a second 
mobilization attempt was allowed but not required per protocol. After at least 1.5 × 106 
CD34+ cells were collected, patients underwent a second registration and proceeded to the 
transplant component of planned treatment. For patients between 61 and 65 years old, each 
site had to select either CBV (carmustine [BCNU]/cyclophosphamide/etoposide) or BEAM 
(BCNU/etoposide/cytarabine/melphalan) as the sole preparative regimen (Chopra, et al 
1993, Reece, et al 1994) for that site. For patients aged less than 61 years, the sites had to 
select either CBV, BEAM, or total body irradiation/cyclophosphamide/etoposide 
(Nademanee, et al 1995) as the sole preparative regimen.
Minimal residual disease (MRD) was assessed at baseline and post-induction from 
peripheral blood. Genomic tumour DNA was extracted from FPE formalin-fixed paraffin-
embedded tissue or bone marrow aspirate mononuclear cells. Polymerase chain reaction 
(PCR) amplification of IGH VDJ, IGH DJ, and IGK regions was performed followed by 
next-generation sequencing to determine the tumour clonotype(s) (Adaptive Biotechnologies 
Corp, South San Francisco, CA)(Faham, et al 2012). DNA from peripheral blood 
mononuclear cells (PBMC) and plasma was amplified and sequenced to determine 
lymphoma molecules per million diploid genomes. If either the PBMC or the plasma sample 
yielded lymphoma clones, then the patient was deemed to be MRD positive.
Study Assessments
Baseline evaluations included documentation of disease-related signs and symptoms, a 
physical examination, bone marrow biopsy and radiographic studies, including CT of the 
neck, chest, abdomen and pelvis, and a PET scan. The best clinical response was determined 
by investigators according to the Revised Response Criteria for Malignant Lymphoma 
(Cheson, et al 2007). In the RH arm, response was assessed by CT scan after cycles 2 and 4, 
and a PET scan was done after cycle 4 but prior to Auto-HCT. In the RB arm, CT scans were 
specified after cycles 4 and 6, and a PET scan was done after cycle 6 but prior to Auto-HCT. 
After Auto-HCT and after removal from study treatment, long-term follow up assessments 
(including survival and disease status information) were performed every 3 months for 1 
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year, every 6 months for 2 year, then annually thereafter until either patient death or 8 years 
after registration. Patients who discontinued study treatment with stable disease or better had 
CT scans every 6 months for 3 years and annually thereafter until disease progression.
Safety monitoring included the recording of adverse events and physical examination 
findings, vital signs, and routine haematology and serum chemistries. Adverse events were 
graded using the National Cancer Institute’s Common Terminology Criteria for Adverse 
Events, version 4 (http://evs.nci.nih.gov/ftp1/CTCAE/
CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf).
Statistical Analysis
The primary objective of this Phase II design was to select a regimen for further 
development, and the primary endpoint is estimated 2-year PFS. Recent SWOG experience 
in this patient population in S0213 (Bernstein, et al 2013) and S0601 (Till, et al 2016) 
suggested a historical 2-year PFS of 68%. In order to proceed with development, the 
observed 2-year PFS on the corresponding arm must be at least 75%. Under the original 
design and sample size, this threshold corresponds not only to a 1-sided 0.05 level test of the 
null hypothesis that the true 2-year PFS is 68%, but also approximates the outcomes 
observed with the transplant regimen of the Nordic Lymphoma Group (Geisler, et al 2008).
Interim analyses of stem cell collection data on both treatment arms was conducted by the 
statistical centre. Either arm would be considered unacceptably toxic if the true stem cell 
collection failure rate exceeded 10%. If, among the first 20 eligible patients on either arm, 
more than 4 (20%) were unable to receive transplant because of inadequate stem cell 
collection, then protocol accrual would be held and consideration would be given to 
modifications or closure of that arm. These analyses correspond to 1-sided 0.05 level tests of 
the null hypothesis that the true failure rate is 10% or less.
Secondary endpoints included ORR, CR, OS, toxicities and MRD analysis. The probability 
of response or a particular toxicity can be estimated to be within at worst 11% (95% 
confidence interval [CI]) with 80 patients per arm. Any adverse event with at least a 5% 
probability would be seen at least once (98% chance). This protocol also assessed the 
association of MRD status at the end of induction therapy, prior to stem cell transplant, with 
PFS. PFS and OS estimates (with 95% CI) were calculated using Kaplan-Meier methods 
(Kaplan and Meier 1958). To minimize selection bias, a landmark analysis at 3 months for 
RH and at 6 months for RB was used for comparing PFS between transplanted and non-
transplanted patients. In this analysis, only patients on RH with at least 3 months of follow-
up without progression or patients on RB with 6 months of follow-up without progression 
were included, and the subsequent progression-free time after 3 months of follow-up for RH 
and after 6 months of follow-up for RB were compared. Four patients on RB who did not 
receive Auto-HCT were excluded from this landmark analysis, as three patients were 
censored and one patient progressed within the 6-months landmark time. The estimated 2-
year PFS for patients on RB who achieved MRD-negative status at the end of induction was 
also calculated by Kaplan-Meier methods using landmark analysis at time of specimen 
collected for MRD testing. Comparisons of response rate and toxicity rate between treatment 
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arms were performed using Fisher’s exact test with two-sided alpha of 0.05. Data as of 10 
February 2016 were included in the analyses.
Results
Patients
Patient characteristics are detailed in Table II. This study was closed after 53 patients were 
accrued: 18 in RH and 35 in RB arms (RH arm closing first). One patient on RH who did not 
receive any randomized therapy due to the closure of RH arm for safety was excluded from 
all endpoint analyses. The groups were well-balanced (Table II) with the exception of more 
females in the RH group. The median age was 57 (range, 33–64) years in the RB arm and 58 
(range, 44–66) years in the RH arm. Ninety-one per cent of the patients in the RB arm and 
94% of the patients in the RH arm had stage IV disease. Eighty-six per cent of the patients in 
the RB arm and 82% of the patients in the RH arm had bone marrow involvement. Ninety-
one per cent of the patients in the RB arm and 88% of the patients in the RH arm had extra-
nodal disease. Lastly, 37% of the patients in the RB arm and 35% of the patients in the RH 
arm were considered intermediate/high risk by MIPI score. Approximately 20% of the 
patients in each arm were considered high risk as determined by a Ki67 score > 30%.
Efficacy
The ORR was 94.1% in the RH arm versus 82.9% in the RB arm (p=0.4). The CR rates were 
40% and 35% for RB and RH, respectively, and the PR rates were 43% and 59% for RB and 
RH, respectively. One patient in the RH arm and 6 patients in the RB arm were not evaluable 
and considered to be non-responders (did not receive radiographic imaging). The median 
follow-up was 37 months in the RH arm and 33 months in the RB arm. The estimated 2-year 
PFS was 81% vs. 82% and estimated 2-year OS was 87% vs. 88% for RB and RH 
respectively (Figs 2–3). In the RH arm, 5 patients received Auto-HCT on protocol, and 4 
patients received Auto-HCT off protocol (discontinued therapy early for toxicities). The 2-
year PFS estimates from the landmark at 3 months of follow-up are 75% vs. 88% (p=0.43) 
for patients that underwent Auto-HCT versus those who did not. In the RB arm, 21 patients 
received Auto-HCT on protocol, 2 received Auto-HCT off protocol, and 12 patients did not 
receive Auto-HCT. The 2-year PFS estimates from the landmark at 6 months of follow-up 
for patients who did not or did receive Auto-HCT was 60% vs. 81% (p=0.20).
Safety
The RH arm had significantly more marrow toxicity compared to the RB arm, with 
increased Grade 3 or 4 thrombocytopenia (71% vs. 17%) (p<0.001), anaemia (59% vs. 
8.6%) (p<0.001), neutropenia (65% vs. 34%) (p=0.07), and febrile neutropenia (29% vs. 
14%) (p=0.26) (Table III). The RB arm also had fewer observed Grade 3 or 4 non-
haematological adverse events, but numbers are too small for a definitive comparison. Grade 
3 or 4 non-haematological adverse events that occurred in greater than 5% of the patients on 
the RH arm were hypokalaemia (29%), hypophosphataemia (24%), hyperglycaemia (12%), 
aspartate transaminase (AST) elevation (5.9%), alanine transaminase (ALT) elevation 
(5.9%), catheter-related infection (5.9%), dehydration (5.9%), diarrhoea (5.9), epistaxis 
(5.9%), nausea (5.9), rash (5.9%) and syncope (5.9%). The sole grade 3 or 4 non-
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haematological adverse event that occurred in greater than 5% of patients on the RB arm 
was hypokalaemia (5.7%).
Twenty-six patients did not finish the course of induction chemotherapy followed by Auto-
HCT. On the RH arm, 7/17 patients could not finish induction chemotherapy, mostly 
because of delayed platelet recovery (Table IV). An additional 5 patients could not mobilize 
an adequate number of stem cells after cycle 2 of induction chemotherapy. This failure to 
collect an adequate number of stem cells triggered the early stopping rules, and the RH arm 
was closed. On the RB arm, 8/35 could not finish induction chemotherapy and 6 did not 
undergo Auto-HCT per protocol (Table IV). However, only 2 patients could not mobilize an 
adequate number of stem cells. The detailed reasons for stopping therapy early are listed in 
Table IV. The entire study was halted and closed because the RH arm encountered the early 
stopping rule. A result was a smaller sample size of the whole study, which limited the 
precisions around our PFS estimates.
MRD analysis
This study also analysed MRD status post-induction therapy via NGS. Twenty-seven 
patients consented to the optional MRD analysis, with 12 paired specimens (pre- and post-
induction therapy, 2 in RH and 10 in RB). In the RH arm, 2 patients were MRD positive at 
baseline; both became MRD negative at the end of induction. In the RB arm, 1 patient was 
MRD negative at baseline, and 9 patients were MRD positive. Seven out of nine patients 
converted to MRD negativity at the end of induction (MRD negative rate of 78%). 
Interestingly, the remaining 2 patients that were MRD positive at end of induction had 
discordant MRD results between the PBMC and plasma samples. For both patients, MRD 
analysis of the PBMC sample yielded low positive MRD at the end of induction (One patient 
had a 6570-fold reduction and another patient had 22000-fold reduction in the lymphoma 
clonotype per million diploid genome). However, the MRD analysis of the plasma sample 
yielded an MRD negative result. These two patients remain alive and in remission. One 
patient on RB was MRD negative at baseline and remained MRD negative at the end of 
induction. This patient eventually developed progressive disease.
There were 3 additional patients that were missing the baseline MRD analysis specimens 
(not included in the 12 paired samples), but were MRD negative at the end of induction. One 
of the 10 patients who was MRD negative at end of induction died approximately 3 months 
after receiving protocol Auto-HCT, and the rest remain in remission, with a 2-year landmark 
PFS of 90% (95% CI: 47.3%, 98.5%).
Discussion
In this randomized multicentre phase II prospective trial, we showed that both R-
hyperCVAD (RH) and R-bendamustine (RB) are active induction regimens with high overall 
response rates. While the observed complete remission rates were lower than historical 
controls, this may reflect that functional imaging was not mandatory at the first restaging, 
and several patients stopped the study early for toxicity and thus did not finish the induction 
therapy or undergo the post induction FDG scan (Bernstein, et al 2013, Romaguera, et al 
2005). There were significant differences in toxicity, with the RH arm displaying 
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significantly more grade 3 and 4 anaemia, neutropenia and thrombocytopenia. Furthermore, 
almost one-third of patients on the RH arm failed to mobilize even 1.5 × 106 stem cells, 
prompting protocol-specified early termination of accrual to the RH arm. Historically, R-
hyperCVAD was developed as an 8-cycle regimen without stem cell transplantation 
consolidation. Single institution studies shortened the RH regimen to 4 cycles, followed by 
Auto-HCT, which appeared feasible (Till, et al 2008). However, our prospective multicentre 
trial clearly shows that abbreviated RH followed by Auto-HCT is not a viable induction 
strategy when stem cell transplantation is planned. In contrast, the toxicity profile of the RB 
arm was similar to prior trials (Rummel et al 2005; Rummel et al 2013; Flinn et al 2014) and 
well tolerated. However, 40% of the patients did not proceed to Auto-HCT as expected (6% 
for mobilization failure, 6% for progressive disease, 6% for other reasons, 9% for toxicity 
and 14% for patient choice or insurance denial). Although the total number of 14 appears to 
be high, the numbers were low (1–2) for each individual reason given, with the exception of 
patient choice. Because of the small sample size from early trial closure, the true 
significance of this data is unclear. The most common reason for patients not proceeding to 
Auto-HCT was patient choice. It is unclear as to why patients chose not to proceed with 
Auto-HCT. One possibility could be the transition from induction treatment physician to a 
different transplant physician as many centres have a separate transplantation team. It also 
may simply represent the challenges of conducting a randomized multi-step trial involving 
Auto-HCT in the cooperative group setting. However, given that the ORR rate appears 
similar in both RH and RB arms, but RH has more haematological toxicity and stem cell 
mobilization insufficiency, our study supports RB as a more favourable induction backbone 
than RH for MCL.
The trial’s primary endpoint was to target a 2-year PFS estimate of 75%. The 2-year PFS 
estimates of both RH and RB arms were similar at 82% and 81%, respectively. Because the 
study closed prematurely, the precision around the PFS estimates is limited. However, the 2-
year PFS estimate of 81% is higher than the planned 75%. The 2-year OS was also similar in 
both arms at 87% vs. 88%, suggesting that both induction regimens followed by auto-HCT 
may be similar in terms of efficacy, although the small sample sizes limit inference. In the 
RH arm, 5 patients received Auto-HCT on protocol, and 4 patients received Auto-HCT off 
protocol. The 2-year landmark PFS estimates are 75% vs. 88% for patients that underwent 
Auto-HCT versus those who did not, suggesting that Auto-HCT may not substantially affect 
2-year PFS. However, this analysis is limited by the small sample size. In the RB arm, 21 
patients received Auto-HCT on protocol, 2 received Auto-HCT off protocol and 12 patients 
did not receive Auto-HCT. Although the 2-year landmark PFS estimates were appearing 
more promising for patients who received Auto-HCT (81% vs. 60%) (p=0.20), this 
difference does not meet statistical significance.
Minimal residual disease (MRD) appears to be a potent predictor of outcome, and was 
included as an optional correlative study. Historically, real-time quantitative PCR analysis of 
rearranged immunoglobulin heavy chain (IGH) genes and multicolour flow cytometry have 
been used for MRD assessment in MCL (Pott 2011). Studies using these methods show that 
MRD negative status post therapy can predict for long term remission (Bottcher, et al 2008, 
Pott, et al 2010). However, these approaches have a number of limitations, including low 
sensitivity, failure of marker identification, and requirement of patient-specific strategies, 
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which is more cumbersome. NGSuses locus-specific primer sets of IGH and IGK regions to 
amplify and sequence cancer-derived clones (Faham, et al 2012). These cancer-derived 
sequences are then used as targets that assess for the presence of MRD in follow-up samples. 
In our study, we evaluated MRD status with NGS technology. Twenty-seven patients 
consented to MRD testing, with 12 paired samples of both pre- and post-induction material 
(peripheral blood). Despite this limited sample size, both RH and RB achieved a relatively 
high rate of MRD negative status. Patients with conversion from MRD positive to MRD 
negative status post-induction had excellent outcomes with a 2-year landmark PFS of 90%; 
three patients did not proceed to Auto-HCT. We also observed discordance between MRD 
results from PBMC and plasma samples. It is unclear whether MRD results from PBMC or 
plasma samples are more sensitive or specific. Two patients were low-level MRD positive 
(low number of molecules) by PMBC and negative by plasma at the end of induction. These 
two patients had a dramatic reduction in their lymphoma clonotype molecules (6570-fold for 
one and 22000-fold for another) and still remain in remission. The clinical significance of 
low level MRD positivity is unknown at this time and will need to be evaluated in future 
studies. Although these provocative findings require confirmation in a larger study, our data 
suggest that NGS-based MRD-negative status is feasible after RB and could become a new 
endpoint for future studies and allow for more rapid evaluation of new treatment strategies.
The Nordic Lymphoma Group introduced the concept of adding cytarabine to the induction 
regimen of MCL. In their single arm prospective study, the addition of cytarabine to 
induction followed by Auto-HCT resulted in a 6-year OS of 70% and PFS of 66% (Geisler, 
et al 2008). Of the 160 patients, 145 (91%) were able to collect stem cells and proceed to 
Auto-HCT. Although this was not a randomized trial, this argues for inclusion of cytarabine 
in the induction regimen. A recent publication from the European Mantle Cell Lymphoma 
Network (Hermine, et al 2016) compared 6 cycles of R-CHOP to 6 cycles of alternating R-
CHOP and R-DHAP (rituximab, dexamethasone, high-dose cytarabine, cisplatin) as 
induction regimen and suggested that the addition of cytarabine to induction chemotherapy 
improves outcomes post Auto-HCT. This study showed an improved 5-year PFS in the 
cytarabine group (65% vs. 44%). It may appear that the result from this study is 
contradictory to our study, as our conclusion was to avoid RH, a cytarabine-containing 
regimen. However, there are a number of similarities in both studies, and the difference lies 
in the interpretation of the data. For example: 1) the confirmed CR rate of R-CHOP/R-
DHAP was 38%, which is similar to the confirmed CR of RB (40%); 2) the MRD negative 
rate from R-CHOP/R-DHAP was 79%, which is similar to the MRD negative rate from RB 
(78%); 3) the 2-year PFS and OS from R-CHOP/R-DHAP appear similar to the 2-year PFS 
and OS from RB. These findings would suggest that, although the addition of cytarabine into 
the induction therapy is advantageous to R-CHOP, it may not be necessary when compared 
to RB. Finally, the stem cell collection failure rate was much higher in the R-CHOP/R-
DHAP arm as compared to the R-CHOP arm (34% vs. 16%). Although the Nordic 
Lymphoma Group did not have problems with stem cell collection with the inclusion of 
cytarabine, it appears that the inclusion of cytarabine and cisplatin (R-DHAP) contributes to 
stem cell mobilization failure.
A variety of novel therapies have been tested in recent years for relapsed/refractory MCL. 
Bortezomib, a proteasome inhibitor, has demonstrated an ORR of 33% and a CR rate of 8% 
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in this setting (Fisher, et al 2006). Patients treated with the immunomodulatory agent 
lenalidomide were shown in a phase II trial to have an ORR of 35% and a CR rate of 12% 
(Zinzani, et al 2013). Ibrutinib, a Bruton tyrosine kinase inhibitor (Wang, et al 2013), has 
shown an ORR of 68% and a CR of 21%. These agents are now being incorporated into the 
induction setting as combination therapies. Early results from an induction trial of 
lenalidomide plus rituximab showed an ORR of 92%, CR of 64% and a 2-year PFS of 85% 
(Ruan, et al 2015). The ORR and PFS were similar to those in our study and other induction 
regimens. However, this was a single arm study that excluded patients with high-risk MIPI 
score (unless there were contraindications to chemotherapy) and required patients to be 
treated for at least 36 cycles of therapy unless there was excess toxicity or progressive 
disease. These results need to be confirmed in a larger randomized trial with longer follow-
up time. It is possible that the addition of novel therapies into induction regimens could 
result in greater CR rates, higher MRD negative responses post-induction, and longer PFS. 
Although the current standard treatment for younger patients is consolidation in first CR 
post-induction with Auto-HCT, it is possible that inclusion of novel therapies into induction 
or as consolidation may change this standard in the future. The current European Network 
younger trial and future US intergroup trials will attempt to answer this provocative 
question.
Overall, significant progress has been made in understanding the molecular biology of MCL, 
and that has translated into improved outcome. The median OS of patients with MCL has 
been extended from 2.7 years to 4.8 years from the time period of 1975–1996 to 1996–2004 
(Herrmann, et al 2009). Since then, other trials have further shown an improvement in OS. 
The Nordic group used an induction regimen of R-maxi-CHOP alternating with cytarabine 
followed by Auto-HCT, showing a median event-free survival (EFS) of 7.4 years and median 
OS of greater than 10 years (Geisler, et al 2012). Many novel agents have been discovered 
and will certainly extend the median OS even further.
In conclusion, this SWOG-led NCTN trial showed that RH was difficult to incorporate in a 
multicentre setting because of toxicity and inadequate stem cell mobilization, and is thus not 
ideal for future development in this setting. In contrast, RB had high response rates, a 78% 
MRD negativity rate, and was generally well tolerated with successful stem cell 
mobilization. In addition, patients achieving MRD negative status after induction had 
excellent outcomes reflected by a 2-year landmark PFS of 90%. We recognize that 40% of 
the patients on the RB arm did not proceed to Auto-HCT per protocol and that the sample 
size was small. Thus, the results of this trial need to be confirmed. The current Eastern 
Cooperative Oncology Group-led NCTN trial (NCT 01415752) using RB with or without 
bortezomib, followed by rituximab with or without lenalidomide, could support our 
observation. Upon confirmation, future trials should focus on MRD analysis as primary 
endpoints for induction trials, as well as the role of Auto-HCT consolidation therapy in 
patients who are MRD negative post-induction therapy.
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Figure 1. Study schema
Ara-C = cytarabine; BEAM = carmustine [BCNU]/etoposide/cytarabine/melphalan; CBV = 
carmustine [BCNU], cyclophosphamide, etoposide; Cy, cyclophosphamide; HCVAD = ; 
HyperCVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin and 
dexamethasone, alternating with high dose cytarabine and methotrexate) MTX, = 
methotrexate; PR = partial response; R = rituximab; TBI = total body irradiation; VP16 = 
etoposide.
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Figure 2. Two-year progression-free survival
HCVAD/MTX/Ara-C = HyperCVAD (hyperfractionated cyclophosphamide, vincristine, 
doxorubicin and dexamethasone, alternating with high dose cytarabine and methotrexate); R 
= rituximab.
Chen et al. Page 15
Br J Haematol. Author manuscript; available in PMC 2018 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. Two-year overall survival
HCVAD/MTX/Ara-C = HyperCVAD (hyperfractionated cyclophosphamide, vincristine, 
doxorubicin and dexamethasone, alternating with high dose cytarabine and methotrexate); R 
= rituximab.
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Table I
Study drugs by dose, days administered, and route.
Cycle 1 and 3 Dose Days Route
Rituximab 375 mg/m2 1 IV
Cyclophosphamide 300 mg/m2 2–4 IV
Doxorubicin 16.6 mg/m2 5–7 IV
Vincristine 1.4 mg/m2 (cap 2) 5 and 12 IV
Dexamethasone 40 mg 2–5, 12–15 IV or PO
Cycle 2 and 4 Dose Days Route
Rituximab 375 mg/m2 1 IV
Methotrexate 200 mg/m2 IV over 2 h
800 mg/m2 IV over 22 h
2 IV
Cytarabine 3 g/m2 3–4 IV
Rituximab 375 mg/m2 1 IV
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Table II
Patient characteristics
Characteristics RH (N=17)* RB (N=35) P-value
Age, years 59 (44–66) 57 (33–64) 0.23
Male/female 9 (53%)/8 (47%) 32 (91%)/3 (9%) 0.003
Performance status
 0 11 (65%) 26 (74%) 0.52
 1 6 (35%) 9 (26%)
Disease stage
 III 1 (5.9%) 3 (8.5%) 1.00
 IV 16 (94.1%) 32 (91.4%)
Bulky disease 1 (6%) 3 (9%) 1.00
B symptoms 6 (35%) 10 (29%) 0.75
Bone marrow involvement 14 (82%) 30 (86%) 1.00
Extranodal involvement 15 (88%) 32 (91%) 1.00
Elevated lactate dehydrogenase 5 (29%) 9 (26%) 1.00
Ki67 (N=46)
 <10% 20% 10%
 10–30% 60% 68% 0.58
 >30% 20% 22%
MIPI score 1.00
 Intermediate/high 6 (35%) 13 (37%)
 Low risk 11 (65%) 22 (63%)
MIPI, mantle cell lymphoma International Prognostic Index; RB, rituximab plus bendamustine; RH, R-HyperCVAD (rituximab with 
hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone, alternating with high dose cytarabine and methotrexate)
*18 patients randomized to RH. However, 1 patient randomized to RH on the day RH arm was closed. That patient did not receive RH and instead 
received RB as per investigator choice. Thus only 17/18 patients were included in analysis.
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Table III
Adverse events
Grade 3/4 toxicities (induction phase) RH (N=17) RB (N=35)
Anaemia 59% 8.6%
Neutropenia 65% 34%
Febrile neutropenia 29% 14%
Thrombocytopenia 71% 17%
Hypokalaemia 29% 5.7%
Hypophosphataemia 24% 2.9%
Hyperglycaemia 12% 0%
ALT increased 5.9% 0%
AST increased 5.9% 0%
Catheter-related infection 5.9% 2.9%
Dehydration 5.9% 0%
Diarrhoea 5.9% 0%
Epistaxis 5.9% 0%
Nausea 5.9% 0%
Rash 5.9% 2.9%
Syncope 5.9% 0%
ALT, alanine transaminase; AST, aspartate transaminase; RB, rituximab plus bendamustine; RH, R-HyperCVAD (rituximab with hyperfractionated 
cyclophosphamide, vincristine, doxorubicin and dexamethasone, alternating with high dose cytarabine and methotrexate)
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Table IV
Reasons for discontinuations
Reasons for discontinuing treatment/stopping before Auto-HCT RH (N=17)
12/17
RB (N=35)
14/35
Failure to collect stem cells 5 2
Thrombocytopenia 5
Patient choice 4
Progressive disease 2
Pancytopenia 1
Neutropenia 1
Allergy 1
Seizure 1
Insurance denial 1
Others 1 2
Auto-HCT, autologous haematopoietic stem cell transplantation; RB, rituximab plus bendamustine; RH, R-HyperCVAD (rituximab with 
hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone, alternating with high dose cytarabine and methotrexate)
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